Antibody Information

General Information of This Antibody

Antibody ID	ANI0KYKHI
Antibody Name	BA-130-03-02
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

LC A032D/HC Y052K [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 23)	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 27)	Positive HER2 expression (EPHA2+++/++)
Method Description	To establish ductal breast cancer model, 5 x 10⁶ cells were implanted into the right flank of athymic nu/nu female donor mice. When tumors reached ~100 mm³ mice were randomly allocated to treatment groups. The dose of ADC was 3 mg/kg.
In Vivo Model	BT474 CDX model
In Vitro Model	Invasive breast carcinoma	BT-474 cells		CVCL_0179

References

Ref 1	Conditionally active anti-her2 antibodies, antibody fragments their immunoconjugates and uses thereof; 2021-07-29.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.